SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy

Advanced Drug Delivery Reviews

Volumn 46, Issue 1-3, 2001, Pages 169-185

  Maeda, Hiroshi ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Enhanced permeability and retention effect; Neocarzinostatin; Poly(styrene co maleic acid anhydride) neocarzinostatin conjugate; Protein modification; Pyran neocarzinostatin conjugate

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MALEIC ANHYDRIDE; POLY(MALEIC ACID STYRENE)NEOCARZINOSTATIN; POLY(MALEIC ACID-STYRENE)NEOCARZINOSTATIN; POLYMER; POLYSTYRENE DERIVATIVE; ZINOSTATIN;

ANIMAL; ARTICLE; CHEMISTRY; HUMAN; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MALEIC ANHYDRIDES; NEOPLASMS; POLYMERS; POLYSTYRENES; ZINOSTATIN;

EID: 0035291191     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00134-4     Document Type: Article

References (66)

1. H. Maeda, Neocarzinostatin in cancer chemotherapy, Anticancer Res. 1 (1981) 175-186.
2. T. Oda, F. Sato, H. Yamamoto, M. Akagi, H. Maeda, Cytotoxicity of SMANCS in comparison with other anticancer agents against various cells in culture, Anticancer Res. 9 (1989) 261-266.
3. B.F. Issell, A.W. Prestaykyo, R.L. Comis, S.F. Crook, Zinostatin, Cancer Treat. Rep. 6 (1979) 239-249.
4. H. Maeda, Y. Sano, J. Takeshita, Z. Iwai, H. Kosaka, T. Marubayashi, Y. Matsukado, A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin. Theoretical considerations behind a two-compartment model for continuous infusion via an internal carotid artery, Cancer Chemother. Pharmacol. 5 (1981) 243-249.
5. H. Maeda, J. Takeshita, A. Yamashita, Lymphotropic accumulation of an antitumor antibiotic protein neocarzinostatin, Eur. J. Cancer 16 (1980) 723-731.
6. F.C. Courtice, The origin of lipoprotein in lymph, in: H.S. Meyersen (Ed.), Lymph and the Lymphatic System, C.C Thomas, Springfield, IL, 1963, pp. 89-126.
7. H. Maeda, Chemical and biological characterization of succinyl neocarzinostatin, J. Antibiot. 27 (1974) 303-311.
8. H. Maeda, J. Takeshita, R. Kanamaru, A lipophilic derivative of neocarzinostatin. A polymer conjugation of antitumor protein antibiotic, Int. J. Pept. Protein Res. 14 (1979) 81-87.
9. H. Maeda, M. Ueda, T. Morinaga, T. Matsumoto, Conjugation of poly(styrene-comaleic acid) derivative to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties, J. Med. Chem. 29 (1985) 455-461.
10. H. Maeda, T. Oda, Y. Matsumura, M. Kimura, Improvements of pharmacological properties of protein-drugs by tailoring with synthetic polymers, J. Bioact. Compat. Polym. 3 (1988) 27-43.
11. T. Oda, T. Morinaga, H. Maeda, Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane, Proc. Soc. Exp. Biol. Med. 181 (1986) 9-17.
12. F. Suzuki, T. Munakata, H. Maeda, Interferon induction by SMANCS. A polymer conjugated derivative of neocarzinostatin, Anticancer Res. 8 (1988) 97-104.
13. F. Suzuki, R.B. Pollard, S. Uchimura, T. Munakata, H. Maeda, Role of natural killer cells and macrophages in the non-specific resistance to tumors in mice stimulated with SMANCS. A polymer-conjugated derivative of neocarzinostatin, Cancer Res. 50 (1990) 3897-3904.
14. Y. Takakura, A. Takagi, M. Hashida, H. Sezaki, Disposition and tumor localization of mitomycin C-dextran conjugate in mice, Pharmacol. Res. 4 (1987) 293-300.
15. S. Sakamoto, H. Maeda, T. Matsumoto, J. Ogata, Experimental and clinical studies on the formation of antibody to neocarzinostatin, a new protein antibiotic, Cancer Treat Rep. 62 (1978) 2063-2070.
16. H. Maeda, T. Matsumoto, T. Konno, K. Iwai, M. Ueda, Tailor-making of protein drugs by polymer conjugation for tumor targeting, a brief review on SMANCS, J. Protein Chem. 3 (1984) 181-193.
17. H. Maeda, J. Takeshita, Degradation of neocarzinostatin by blood sera in vitro and its inhibition by diisopropylfluorophosphate and N-ethylmaleimide, Gann 66 (1975) 523-527.
18. S. Hirayama, F. Sato, T. Oda, H. Maeda, Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase: comparative study with neocarzinostatin, Jpn. J. Antibiot. 39 (1986) 815-822.
19. H. Maeda, Y. Matsumura, Tumoritropic and lymphotropic principles of macromolecular drugs, Crit. Rev. Ther. Drug Carrier Syst. 6 (1989) 193-210.
20. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS, Cancer Res. 6 (1986) 6387-6392.
21. M. Suzuki, K. Hori, I. Abe, S. Saito, H. Sato, A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II, J. Natl. Cancer Inst. 67 (1981) 663-669.
22. M. Suzuki, T. Takahashi, T. Sato, Medial regression and its functional significance in tumor-supplying host arteries, Cancer 59 (1987) 444-450.
23. S.A. Skinner, P.J.M. Tutton, E. O'Brien, Microvascular architecture of experimental colon tumors in the rat, Cancer Res. 50 (1991) 2411-2417.
24. J. Folkman, Tumor angiogenesis, Adv. Cancer Res. 19 (1974) 331-358.
25. J. Folkman, M. Klagsburn, Angiogenic factors, Science 235 (1987) 442-447.
26. D.R. Senger, S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, H.F. Dvorak, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascitic fluid, Science 219 (1983) 983-985.
27. 3]bradykinin in ascitic fluid from a patient with gastric cancer, J. Biol. Chem. 263 (1988) 16051-16056.
28. Y. Matsumura, M. Kimura, T. Yamamoto, H. Maeda, Involvement of kinin-generating cascade in enhanced vascular permeability in tumor tissue, Jpn. J. Cancer Res. 79 (1988) 1327-1334.
29. K. Iwai, H. Maeda, T. Konno, Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image, Cancer Res. 44 (1984) 2114-2121.
30. R. Kamata, T. Yamamoto, K. Matsumoto, H. Maeda, A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs, Infect. Immunol. 48 (1985) 747-753.
31. H. Maeda, A. Molla, Pathogenic potentials of bacterial proteases, Clin. Chim. Acta 185 (1989) 357-368.
32. H.I. Peterson, K.L. Appelgren, Experimental studies on the uptake and retention of labeled proteins in a rat tumor, Eur. J. Cancer 9 (1973) 543-547.
33. 1-acid glycoprotein: uptake by inflammatory and tumor tissue, Br. J. Exp. Patholol. 59 (1978) 601-608.
34. A. Kobayashi, T. Oda, M. Maeda, Protein binding of macromolecular anticancer agent SMANCS: characterization of poly(styrene-comaleic acid) derivatives as an albumin binding ligand, J. Bioact. Compat. Polym. 3 (1988) 319-333.
35. T. Konno, H. Maeda, K. Iwai, S. Maki, S. Tashiro, M. Uchida, Y. Miyauchi, Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium, Cancer 54 (1984) 2367-2374.
36. T. Konno, T. Maeda, M. Mochinaga, S. Tashiro, M. Uchida, I. Yokoyama, Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report, Eur. J. Cancer Clin. Oncol. 19 (1983) 1053-1065.
37. S.M. Larson, Mechanism of localization of gallium-67 in tumors, Semin. Nucl. Med. 8 (1978) 193-203.
38. Y. Matsumura, H. Kato, H. Maeda, Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC, Agents Actions 29 (1990) 172-180.
39. H. Maeda, Y. Matsumura, M. Kimura, K. Maruo, Kinin-generating cascade in cancer. Clinical and in vitro study and utilization for tumor targeting, J. Cancer Res. Clin. Oncol. 116 (Suppl.) (1990) 246.
40. Y. Matsumura, K. Maruo, M. Kimura, T. Yamamoto, T. Konno, H. Maeda, Kinin-generating cascade in advanced cancer patients and in vitro study, Jpn. J. Cancer Res., in press.
41. D. Armstrong, Pain in bradykinin: Kalldin and kallikrein, Handb. Exp. Pharmacol. 25 (1973) 434-481.
42. B.B. Vergaftig, N.D. Hai, Selective inhibition by mepacrine of the release of rabbit aorta contracting substance evoked by the administration of bradykinin, J. Pharm. Pharmacol. 24 (1972) 159-161.
43. F. Lembeck, 5-Hydroxytryptamine in a carcinoid tumor, Nature 172 (1953) 910-911.
44. L.M. Greenbaum, P. Grebow, M. Johnston, H. Prakath, G. Semente, Pepstatin - an inhibitor of leukokinin formation and ascitic fluid accumulation, Cancer Res. 35 (1975) 706-710.
45. F. Zunino, R. Gambetta, A. Vigevani, S. Penco, C. Gerni, A. di Marco, Biologic activity of daunorubicin linked to proteins via the methylketone side chain, Tumori 67 (1981) 521-524.
46. M. Hashida, A. Kato, T. Kojima, S. Muranishi, H. Sezaki, N. Tanigawa, K. Satomura, Y. Hikasa, Antitumor activity of mitomycin C-dextran conjugate against various murine tumors, Jpn. J. Cancer Res. (Gann) 72 (1981) 226-234.
47. A. Trouet, M. Masquelier, R. Baurain, D. Deprez-De Campeneere, A covalent linkage between daunorubicin and proteins that is stable in serum conjugate: in vitro and in vivo studies, Proc. Natl. Acad. Sci. USA 79 (1982) 626-629.
48. F. Levi-Schaffer, S. Bernstein, A. Meshorer, R. Arnon, Reduced toxicity of daunorubicin by conjugation to dextran, Cancer Treat. Rep. 66 (1982) 107-114.
49. H. Yamamoto, T. Miki, T. Oda, T. Hirano, Y. Sera, M. Akagi, H. Maeda, Reduced bone marrow toxicity of neocarzinostatin by conjugation with divinyl ether-maleic acid copolymer, Eur. J. Cancer 26 (1990) 253-260.
50. K. Iwai, H. Maeda, T. Konno, Y. Matsumura, R. Yamashita, K. Yamasaki, S. Hirayama, Y. Miyauchi, Tumor targeting by arterial administration of lipids: rabbit model with VX-2 carcinoma in the liver, Anticancer Res. 7 (1987) 321-328.
51. K. Oka, Y. Miyamoto, Y. Matsumura, S. Tanaka, T. Oda, F. Suzuki, H. Maeda, Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, SMANCS, in an oily formulation, Pharmacol. Res. 7 (1990) 852-855.
52. T. Konno, H. Maeda, Targeting chemotherapy of hepatocellular carcinoma: arterial administration of SMANCS/ Lipiodol, in: K. Okuda, K.G. Ishak (Eds.), Neoplasms of the Liver, Springer, New York, 1987, pp. 343-352, Chapter 27.
53. S. Noda, S. Konno, J. Tanaka, H. Yamada, N. Yoshitake, Treatment of renal cell carcinoma with intraarterial administration of SMANCS dissolved in Lipiodol, Anticancer Res. 10 (1990) 709-716.
54. Y. Yumoto, K. Jinno, K. Tokuyama, Y. Araki, T. Ishimitsu, H. Maeda, T. Konno, S. Imamoto, K. Ohnishi, K. Okuda, Hepatocellular carcinoma detected by iodized oil, Radiology 154 (1985) 19-24.
55. S. Maki, T. Konno, H. Maeda, Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium, Cancer 56 (1985) 751-757.
56. H. Maeda, Y. Matsumura, T. Oda, K. Sasamoto, Cancer selective macromolecular therapeusis: tailoring of an antitumor protein drug, in: R.E. Feeney, J.R. Whitaker (Eds.), Protein Tailoring for Food and Medical Uses, Marcel Dekker, New York, 1983, pp. 353-382.
57. J. Bartholeyns, S. Moore, Pancreatic ribonuclease: enzymatic and physiological properties of a cross-linked dimer, Science 186 (1974) 444-445.
58. T. Ogino, M. Inoue, Y. Ando, M. Awai, H. Maeda, Y. Morino, Chemical modification of superoxide dismutase. Extension of plasma half-life of the enzyme through its reversible binding to the circulating albumin, Int. J. Pept. Protein Res. 32 (1988) 153-159.
59. T. Takakura, Y. Kaneko, T. Fujita, M. Hashida, H. Maeda, H. Sezaki, Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. I. Synthesis and characterization, J. Pharm. Sci. 78 (1989) 117-121.
60. Y. Takakura, T. Fujita, M. Hashida, H. Maeda, H. Sezaki, Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II. Biopharmaceutical and pharmacological properties, J. Pharm. Sci. 78 (1989) 219-222.
61. M. Kimura, Y. Matsumura, Y. Miyauchi, H. Maeda, A new tactic for the treatment of jaundice: an injectable polymer-conjugated bilirubin oxidase, Proc. Soc. Exp. Biol. Med. 188 (1988) 364-369.
62. C.H.C.M. Buys, A.S.H. Dejong, J.D.W. Bouma, M. Gruber, Rapid uptake by liver sinusoidal cells of serum albumin modified with retention of its compact conformation, Biochim. Biophys. Acta 392 (1975) 95-100.
63. Y. Kamisaki, H. Wada, H. Yagura, A. Matsushima, Y. Inada, Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypoly(ethylene glycol), J. Pharmacol. Exp. Ther. 216 (1981) 410-414.
64. 2-macroglobulin-plasmin complex, Biochemistry 24 (1985) 4586-4592.
65. R.L. Comis, T.W. Griffin, V. Raso, S.J. Ginsberg, Pharmacokinetics of the protein antitumor antibiotic neocarzinostatin after bolus injection in humans, Cancer Res. 39 (1979) 757-761.
66. H. Sato, A. Wakui, M. Hoshi, M. Kurihara, M. Yokoyama, H. Shimizu, Randomized controlled trial of induced hypertension chemotherapy (IHC) using angiotensin II human (TY-10721) in advanced gastric carcinoma (TY-10721 IHC Study Group Report), Jpn. J. Cancer Chemother. 18 (1991) 451-460, in Japanese.